β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights (2) π’ Company Q&A (465) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
| Fiscal year | Segment | Value |
|---|---|---|
| 2024 | Aranesp | 1.34B |
| 2024 | BLINCYTO | 1.22B |
| 2024 | ENBREL | 3.32B |
| 2024 | Prolia | 4.37B |
| 2024 | TEPEZZA | 1.85B |
| 2024 | EVENITY | 1.56B |
| 2024 | TEZSPIRE | 972M |
| 2024 | Otezla | 2.13B |
| 2024 | Repatha (evolocumab) | 2.22B |
π° Explore more revenue segmentation data for Amgen!
Sign up for free or log inπ‘ Learn smarter stock picks with "The Checklist Value Investor β A Smarter Way to Pick Stocks"